Connection

Daniel Judge to Female

This is a "connection" page, showing publications Daniel Judge has written about Female.
Connection Strength

1.058
  1. Long-Term Efficacy and Safety of ARRY-371797 (PF-07265803) in Patients With Lamin A/C-Related Dilated Cardiomyopathy. Am J Cardiol. 2022 11 15; 183:93-98.
    View in: PubMed
    Score: 0.046
  2. Genetic Dilated Cardiomyopathy Due to TTN Variants Without Known Familial Disease. Circ Genom Precis Med. 2020 12; 13(6):e003082.
    View in: PubMed
    Score: 0.040
  3. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. 2020 06; 34(3):357-370.
    View in: PubMed
    Score: 0.039
  4. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid?Cardiomyopathy. J Am Coll Cardiol. 2019 07 23; 74(3):285-295.
    View in: PubMed
    Score: 0.036
  5. The Role of Genetics in Peripartum Cardiomyopathy. J Cardiovasc Transl Res. 2017 Dec; 10(5-6):437-445.
    View in: PubMed
    Score: 0.032
  6. Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis. Amyloid. 2017 Jun; 24(2):92-95.
    View in: PubMed
    Score: 0.032
  7. Multilevel analyses of SCN5A mutations in arrhythmogenic right ventricular dysplasia/cardiomyopathy suggest non-canonical mechanisms for disease pathogenesis. Cardiovasc Res. 2017 01; 113(1):102-111.
    View in: PubMed
    Score: 0.031
  8. Baseline Characteristics Predict the Presence of Amyloid on Endomyocardial Biopsy. J Card Fail. 2017 Apr; 23(4):340-344.
    View in: PubMed
    Score: 0.031
  9. Absence of a Primary Role for SCN10A Mutations in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. J Cardiovasc Transl Res. 2016 Feb; 9(1):87-9.
    View in: PubMed
    Score: 0.029
  10. Why should cardiologists consider genetic testing for hypertrophic cardiomyopathy? JACC Heart Fail. 2015 Feb; 3(2):189-91.
    View in: PubMed
    Score: 0.027
  11. Shared desmosome gene findings in early and late onset arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Transl Res. 2010 Dec; 3(6):663-73.
    View in: PubMed
    Score: 0.020
  12. Use of genetics in the clinical evaluation of cardiomyopathy. JAMA. 2009 Dec 09; 302(22):2471-6.
    View in: PubMed
    Score: 0.019
  13. Comprehensive desmosome mutation analysis in north americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Cardiovasc Genet. 2009 Oct; 2(5):428-35.
    View in: PubMed
    Score: 0.018
  14. Recessive arrhythmogenic right ventricular dysplasia due to novel cryptic splice mutation in PKP2. Hum Mutat. 2006 Nov; 27(11):1157.
    View in: PubMed
    Score: 0.015
  15. Penetrance of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2006 Oct 03; 48(7):1416-24.
    View in: PubMed
    Score: 0.015
  16. Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation. 2006 Apr 04; 113(13):1641-9.
    View in: PubMed
    Score: 0.015
  17. Marfan's syndrome. Lancet. 2005 Dec 03; 366(9501):1965-76.
    View in: PubMed
    Score: 0.014
  18. Reversible dilated cardiomyopathy associated with glucagonoma. Heart. 2004 Jul; 90(7):e44.
    View in: PubMed
    Score: 0.013
  19. Knowledge of Genome Sequencing and Trust in Medical Researchers Among Patients of Different Racial and Ethnic Groups With Idiopathic Dilated Cardiomyopathy. JAMA Cardiol. 2023 01 01; 8(1):33-42.
    View in: PubMed
    Score: 0.012
  20. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2022 08 21; 43(32):e1-e9.
    View in: PubMed
    Score: 0.011
  21. Prevalence and Cumulative Risk of Familial Idiopathic Dilated Cardiomyopathy. JAMA. 2022 02 01; 327(5):454-463.
    View in: PubMed
    Score: 0.011
  22. Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants. Circulation. 2021 11 16; 144(20):1600-1611.
    View in: PubMed
    Score: 0.011
  23. Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy. Circulation. 2021 05 11; 143(19):1852-1862.
    View in: PubMed
    Score: 0.010
  24. International Evidence Based Reappraisal of Genes Associated With Arrhythmogenic Right Ventricular Cardiomyopathy Using the Clinical Genome Resource Framework. Circ Genom Precis Med. 2021 06; 14(3):e003273.
    View in: PubMed
    Score: 0.010
  25. Characterization of microsatellite markers flanking FBN1: utility in the diagnostic evaluation for Marfan syndrome. Am J Med Genet. 2001 Feb 15; 99(1):39-47.
    View in: PubMed
    Score: 0.010
  26. Cadherin 2-Related Arrhythmogenic Cardiomyopathy: Prevalence and Clinical Features. Circ Genom Precis Med. 2021 04; 14(2):e003097.
    View in: PubMed
    Score: 0.010
  27. Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic. Am Heart J. 2021 03; 233:122-131.
    View in: PubMed
    Score: 0.010
  28. Influence of Panel Selection on Yield of Clinically Useful Variants in Arrhythmogenic Right Ventricular Cardiomyopathy Families. Circ Genom Precis Med. 2020 10; 13(5):548-550.
    View in: PubMed
    Score: 0.010
  29. Endomyocardial Biopsy Characterization of Heart?Failure With Preserved Ejection?Fraction and Prevalence of Cardiac Amyloidosis. JACC Heart Fail. 2020 09; 8(9):712-724.
    View in: PubMed
    Score: 0.010
  30. Safety and Utility of Cardiopulmonary Exercise Testing in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. J Am Heart Assoc. 2020 02 04; 9(3):e013695.
    View in: PubMed
    Score: 0.010
  31. FLNC truncations cause arrhythmogenic right ventricular cardiomyopathy. J Med Genet. 2020 04; 57(4):254-257.
    View in: PubMed
    Score: 0.010
  32. SSRI/SNRI Therapy is Associated With a Higher Risk of Gastrointestinal Bleeding in LVAD Patients. Heart Lung Circ. 2020 Aug; 29(8):1241-1246.
    View in: PubMed
    Score: 0.009
  33. Arrhythmogenic Right Ventricular Cardiomyopathy-Associated Desmosomal Variants Are Rarely De Novo. Circ Genom Precis Med. 2019 08; 12(8):e002467.
    View in: PubMed
    Score: 0.009
  34. Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy. J Clin Invest. 2019 07 02; 129(8):3171-3184.
    View in: PubMed
    Score: 0.009
  35. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2019 06 14; 40(23):1850-1858.
    View in: PubMed
    Score: 0.009
  36. Genetic aetiologies should be considered in paediatric cases of acute heart failure presumed to be myocarditis. Cardiol Young. 2019 Jul; 29(7):917-921.
    View in: PubMed
    Score: 0.009
  37. Seven factors predict a delayed diagnosis of cardiac amyloidosis. Amyloid. 2018 Sep; 25(3):174-179.
    View in: PubMed
    Score: 0.009
  38. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018 Sep 13; 379(11):1007-1016.
    View in: PubMed
    Score: 0.009
  39. Managing Secondary Genomic Findings Associated With Arrhythmogenic Right Ventricular Cardiomyopathy: Case Studies and Proposal for Clinical Surveillance. Circ Genom Precis Med. 2018 07; 11(7):e002237.
    View in: PubMed
    Score: 0.009
  40. Identification of sarcomeric variants in probands with a clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC). J Cardiovasc Electrophysiol. 2018 07; 29(7):1004-1009.
    View in: PubMed
    Score: 0.009
  41. Performance of the 2015 International Task Force Consensus Statement Risk Stratification Algorithm for Implantable Cardioverter-Defibrillator Placement in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circ Arrhythm Electrophysiol. 2018 02; 11(2):e005593.
    View in: PubMed
    Score: 0.008
  42. Heart Failure Is Common and Under-Recognized in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Circ Heart Fail. 2017 Sep; 10(9).
    View in: PubMed
    Score: 0.008
  43. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid. 2017 Sep; 24(3):194-204.
    View in: PubMed
    Score: 0.008
  44. Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy. Ann Neurol. 2017 Jul; 82(1):44-56.
    View in: PubMed
    Score: 0.008
  45. Implantable Cardioverter-Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications. J Am Heart Assoc. 2017 Jun 06; 6(6).
    View in: PubMed
    Score: 0.008
  46. Comparison of Features of Fatal Versus Nonfatal Cardiac Arrest in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Am J Cardiol. 2017 07 01; 120(1):111-117.
    View in: PubMed
    Score: 0.008
  47. Evaluation of Structural Progression in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. JAMA Cardiol. 2017 03 01; 2(3):293-302.
    View in: PubMed
    Score: 0.008
  48. Cardiac phenotype and long-term prognosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia patients with late presentation. Heart Rhythm. 2017 06; 14(6):883-891.
    View in: PubMed
    Score: 0.008
  49. Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. J Heart Lung Transplant. 2017 Apr; 36(4):380-385.
    View in: PubMed
    Score: 0.008
  50. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016 07 12; 68(2):161-72.
    View in: PubMed
    Score: 0.007
  51. Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. Heart. 2016 02 15; 102(4):303-12.
    View in: PubMed
    Score: 0.007
  52. Safety of American Heart Association-recommended minimum exercise for desmosomal mutation carriers. Heart Rhythm. 2016 Jan; 13(1):199-207.
    View in: PubMed
    Score: 0.007
  53. Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Eur Heart J. 2016 Mar 01; 37(9):755-63.
    View in: PubMed
    Score: 0.007
  54. Fluctuating creatinine in the cardiac unit. Clin Chim Acta. 2015 Jul 20; 447:52-4.
    View in: PubMed
    Score: 0.007
  55. Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis. J Cardiovasc Transl Res. 2015 Jun; 8(4):264-8.
    View in: PubMed
    Score: 0.007
  56. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015 May; 8(3):519-26.
    View in: PubMed
    Score: 0.007
  57. Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. Circ Cardiovasc Genet. 2015 Jun; 8(3):437-46.
    View in: PubMed
    Score: 0.007
  58. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Transl Res. 2015 Mar; 8(2):117-27.
    View in: PubMed
    Score: 0.007
  59. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. Eur Heart J. 2015 Apr 07; 36(14):847-55.
    View in: PubMed
    Score: 0.007
  60. Outcomes and ventricular tachycardia recurrence characteristics after epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm. 2015 Apr; 12(4):716-25.
    View in: PubMed
    Score: 0.007
  61. Exercise has a disproportionate role in the pathogenesis of arrhythmogenic right ventricular dysplasia/cardiomyopathy in patients without desmosomal mutations. J Am Heart Assoc. 2014 Dec; 3(6):e001471.
    View in: PubMed
    Score: 0.007
  62. Yield of serial evaluation in at-risk family members of patients with ARVD/C. J Am Coll Cardiol. 2014 Jul 22; 64(3):293-301.
    View in: PubMed
    Score: 0.007
  63. Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy. Ann Neurol. 2014 Oct; 76(4):541-9.
    View in: PubMed
    Score: 0.007
  64. Novel and highly lethal NKX2.5 missense mutation in a family with sudden death and ventricular arrhythmia. Pediatr Cardiol. 2014 Oct; 35(7):1206-12.
    View in: PubMed
    Score: 0.006
  65. Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: distinguishing features when the diagnosis is unclear. Circ Arrhythm Electrophysiol. 2014 Apr; 7(2):230-6.
    View in: PubMed
    Score: 0.006
  66. Angiotensin II-dependent TGF-? signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. J Clin Invest. 2014 Jan; 124(1):448-60.
    View in: PubMed
    Score: 0.006
  67. Missense mutations in plakophilin-2 cause sodium current deficit and associate with a Brugada syndrome phenotype. Circulation. 2014 Mar 11; 129(10):1092-103.
    View in: PubMed
    Score: 0.006
  68. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013 Dec; 6(6):1011-20.
    View in: PubMed
    Score: 0.006
  69. A Pkd1-Fbn1 genetic interaction implicates TGF-? signaling in the pathogenesis of vascular complications in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2014 Jan; 25(1):81-91.
    View in: PubMed
    Score: 0.006
  70. Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm. 2013 Nov; 10(11):1661-8.
    View in: PubMed
    Score: 0.006
  71. Mutation-positive arrhythmogenic right ventricular dysplasia/cardiomyopathy: the triangle of dysplasia displaced. J Cardiovasc Electrophysiol. 2013 Dec; 24(12):1311-20.
    View in: PubMed
    Score: 0.006
  72. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013 Oct 01; 62(14):1290-1297.
    View in: PubMed
    Score: 0.006
  73. Malignant arrhythmogenic right ventricular dysplasia/cardiomyopathy with a normal 12-lead electrocardiogram: a rare but underrecognized clinical entity. Heart Rhythm. 2013 Oct; 10(10):1484-91.
    View in: PubMed
    Score: 0.006
  74. Exercise testing in asymptomatic gene carriers exposes a latent electrical substrate of arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2013 Nov 05; 62(19):1772-9.
    View in: PubMed
    Score: 0.006
  75. Incremental value of cardiac magnetic resonance imaging in arrhythmic risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013 Nov 05; 62(19):1761-9.
    View in: PubMed
    Score: 0.006
  76. Risk stratification in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. Circ Arrhythm Electrophysiol. 2013 Jun; 6(3):569-78.
    View in: PubMed
    Score: 0.006
  77. LMNA-associated cardiocutaneous progeria: an inherited autosomal dominant premature aging syndrome with late onset. Am J Med Genet A. 2013 Jul; 161A(7):1599-611.
    View in: PubMed
    Score: 0.006
  78. The variable natural history of idiopathic dilated cardiomyopathy. Isr Med Assoc J. 2012 Nov; 14(11):666-71.
    View in: PubMed
    Score: 0.006
  79. Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovasc Pathol. 2013 May-Jun; 22(3):189-94.
    View in: PubMed
    Score: 0.006
  80. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012 Aug; 164(2):222-228.e1.
    View in: PubMed
    Score: 0.006
  81. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail. 2012 Nov; 14(11):1199-207.
    View in: PubMed
    Score: 0.006
  82. Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol. 2012 Jun 01; 5(3):499-505.
    View in: PubMed
    Score: 0.006
  83. Genetic testing for dilated cardiomyopathy in clinical practice. J Card Fail. 2012 Apr; 18(4):296-303.
    View in: PubMed
    Score: 0.006
  84. Plasma BIN1 correlates with heart failure and predicts arrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. 2012 Jun; 9(6):961-7.
    View in: PubMed
    Score: 0.005
  85. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol. 2011 Sep 27; 58(14):1485-96.
    View in: PubMed
    Score: 0.005
  86. Reader- and instrument-dependent variability in the electrocardiographic assessment of arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Electrophysiol. 2011 May; 22(5):561-8.
    View in: PubMed
    Score: 0.005
  87. Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome. Sci Transl Med. 2010 Mar 17; 2(23):23ra20.
    View in: PubMed
    Score: 0.005
  88. The change in B-type natriuretic peptide levels over time predicts significant rejection in cardiac transplant recipients. J Heart Lung Transplant. 2009 Jul; 28(7):704-9.
    View in: PubMed
    Score: 0.005
  89. Morphologic variants of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy a genetics-magnetic resonance imaging correlation study. J Am Coll Cardiol. 2009 Apr 14; 53(15):1289-99.
    View in: PubMed
    Score: 0.005
  90. Prolonged RV endocardial activation duration: a novel marker of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm. 2009 Jun; 6(6):769-75.
    View in: PubMed
    Score: 0.004
  91. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med. 2008 Jun 26; 358(26):2787-95.
    View in: PubMed
    Score: 0.004
  92. Familial hypertrophic cardiomyopathy associated with cardiac beta-myosin heavy chain and troponin I mutations. Pediatr Cardiol. 2008 Jul; 29(4):846-50.
    View in: PubMed
    Score: 0.004
  93. Extensive cardiac allograft vasculitis and concurrent fat necrosis 6 years after orthotopic heart transplantation. J Heart Lung Transplant. 2007 Nov; 26(11):1212-6.
    View in: PubMed
    Score: 0.004
  94. Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in the thoracic aortic aneurysm in Marfan syndrome. Circ Res. 2007 Aug 31; 101(5):512-22.
    View in: PubMed
    Score: 0.004
  95. Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2007 Jul 31; 50(5):432-40.
    View in: PubMed
    Score: 0.004
  96. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006 Apr 07; 312(5770):117-21.
    View in: PubMed
    Score: 0.004
  97. The benefit of upgrading chronically right ventricle-paced heart failure patients to resynchronization therapy demonstrated by strain rate imaging. Heart Rhythm. 2006 Apr; 3(4):435-42.
    View in: PubMed
    Score: 0.004
  98. Arrhythmogenic right ventricular dysplasia: a United States experience. Circulation. 2005 Dec 20; 112(25):3823-32.
    View in: PubMed
    Score: 0.004
  99. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005 Mar; 37(3):275-81.
    View in: PubMed
    Score: 0.003
  100. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest. 2004 Dec; 114(11):1586-92.
    View in: PubMed
    Score: 0.003
  101. Short-term effects of right-left heart sequential cardiac resynchronization in patients with heart failure, chronic atrial fibrillation, and atrioventricular nodal block. Circulation. 2004 Nov 30; 110(22):3404-10.
    View in: PubMed
    Score: 0.003
  102. Allelic variation in normal human FBN1 expression in a family with Marfan syndrome: a potential modifier of phenotype? Hum Mol Genet. 2003 Sep 15; 12(18):2269-76.
    View in: PubMed
    Score: 0.003
  103. KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet. 2003 May; 72(5):1154-61.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.